S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Anika Therapeutics Stock Forecast, Price & News

+0.32 (+1.44%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
79,822 shs
Average Volume
98,721 shs
Market Capitalization
$327.39 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Stock Forecast (MarketRank)

Overall MarketRank

2.27 out of 5 stars

Medical Sector

310th out of 1,432 stocks

Surgical & Medical Instruments Industry

37th out of 137 stocks

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
Anika Therapeutics logo

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Stock News Headlines

Anika Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Supplies
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$4.13 million
Pretax Margin


Sales & Book Value

Annual Sales
$147.79 million
Cash Flow
$1.41 per share
Book Value
$19.89 per share


Free Float
Market Cap
$327.39 million

Social Links

Anika Therapeutics Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Anika Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View analyst ratings for Anika Therapeutics
or view top-rated stocks.

What is Anika Therapeutics' stock price forecast for 2022?

3 brokerages have issued 12-month price objectives for Anika Therapeutics' shares. Their ANIK stock forecasts range from $35.00 to $48.00. On average, they anticipate Anika Therapeutics' stock price to reach $43.00 in the next year. This suggests a possible upside of 91.0% from the stock's current price.
View analysts' price targets for Anika Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Anika Therapeutics' stock price performed in 2022?

Anika Therapeutics' stock was trading at $35.83 at the start of the year. Since then, ANIK stock has decreased by 37.2% and is now trading at $22.51.
View the best growth stocks for 2022 here

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Anika Therapeutics

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) posted its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.13. The biotechnology company earned $36.69 million during the quarter, compared to analysts' expectations of $33.90 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 0.92% and a negative net margin of 1.09%. During the same quarter in the prior year, the business posted $0.06 earnings per share.
View Anika Therapeutics' earnings history

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Dr. Cheryl Renee Blanchard Ph.D., Pres, CEO & Director (Age 58, Pay $1.26M)
  • Mr. Michael L. Levitz, Exec. VP, CFO & Treasurer (Age 48, Pay $683.14k) (LinkedIn Profile)
  • Mr. David Colleran, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50, Pay $649.06k)
  • Ms. Anne Nunes, VP of Operations
  • Mr. Mark Namaroff, Exec. Director of Investor Relations & Corp. Communications (Age 59)
  • Mr. Charles Sherwood III, VP & Corp. Legal Counsel
  • Mr. James Chase, Sr. VP of International Sales & Marketing
  • Mr. Bart Bracy, VP of Sales & Marketing of Americas
  • Mr. Ben Joseph, VP of Commercial & Corp. Devel.
  • Ms. Lisa Funiciello, VP of HR

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $22.51.

How much money does Anika Therapeutics make?

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $327.39 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($0.110010) on an earnings per share basis.

How many employees does Anika Therapeutics have?

Anika Therapeutics employs 297 workers across the globe.

When was Anika Therapeutics founded?

Anika Therapeutics was founded in 1992.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for Anika Therapeutics is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at [email protected], or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.